Temozolomide and radiotherapy as first-line treatment of high-grade gliomas

Tumori

Volumn 92, Issue 4, 2006, Pages 299-305

  Corsa, Pietro ^a   Parisi, Salvatore ^a   Raguso, Arcangela ^a   Troiano, Michele ^a   Perrone, Antonio ^a   Cossa, Sabrina ^a   Munafò, Tindara ^a   Piombino, Michele ^b   Spagnoletti, Girolamo ^c   Borgia, Francesco ^c  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b POLICLINICO   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

Anaplastic astrocytoma; Chemotherapy; Glioblastoma; Radiation therapy; Surgery; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; BLOOD TOXICITY; CANCER SURVIVAL; CONTROLLED STUDY; FATIGUE; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; PROGNOSIS; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 33749524261     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200407     Document Type: Review

References (40)

1. DeAngelis LM, Burger PC, Green SB, Cairncross JG: Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol, 44: 691-695, 1998.
2. Galanis E, Buckner J: Chemotherapy for high-grade gliomas. Br J Cancer, 82: 1371-1380, 2000.
3. Del Rowe J, Scott C, Werner-Wasik M, Bahary JP, Curran WJ, Urtasun RC, Fisher B: Single-arm open-label phase II study of intra-venously administrated tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Onc, 18: 1254-1259, 2000.
4. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer, 73: 2585-2597, 1993.
5. Fisher BJ, Scott C, Macdonald DR, Coughlin C, Curran WJ: Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group trial 9507. J Clin Oncol, 19: 1111-1117, 2001.
6. Medical Research Council Brain Tumor Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J Clin Oncol, 19: 509-518, 2001.
7. Glioma Meta-analysis Trialist (GMT) Group: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 35: 1011-1018, 2002.
8. Stupp R, Gander M, Leyvraz S, Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumors. Lancet Oncol, 2: 552-560, 2001.
9. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one(CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res, 47: 5846-5852, 1987.
10. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol, 12: 259-266, 2001.
11. Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P, Rabbitt J, Page M, Nicholas MK, Prados MD: Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 60: 353-357, 2004.
12. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Maradiotherapyin PM, Grisoli F: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendroglioma after standard radiotherapy and chemotherapy. J Clin Oncol, 19: 2449-2455, 2001.
13. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol, 16: 3851-3857, 1998.
14. Gilbert M, Olson J, Yung W: Preradiation treatment of newly diagnosed anaplastic astrocytomas and glioblastoma multiforme using temozolomide. Neurooncol, 2: 264 (abstr 77), 2000.
15. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev, 23: 35-61, 1997.
16. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol, 20: 1375-1382, 2002.
17. Yamini B, Yu X, Gillespie GY, Kufe DW, Weichselbaum RR: Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. Cancer Res, 64: 6381-6384, 2004.
18. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352: 987-996, 2005.
19. Corsa P, Parisi S, Piombino M, Troiano M, Raguso A, Cossa S, Perrone A, Spagnoletti G: A preliminary retrospective study with temozolomide and radiotherapy versus radiotherapy alone for the treatment of high-grade gliomas. Int J Radiat Oncol Biol Phys, 57 (Suppl 2): S378, 2003.
20. Jansen EP, Dewit LG, van Herk M, Bartelink H: Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol, 56: 151-156, 2000.
21. Andersen AP: Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol, 17: 474-484, 1978.
22. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, Hatlevoll R, Lindgren M, Brun A, Lindgren S, Notter G, Andersen AP, Eigen K: Combined modality therapy of operated astrocytomas grade III and IV. Cancer, 47: 649-652, 1981.
23. Shapiro WR, Dean F, Young DF: Treatment of malignant glioma. A controlled study of chemotherapy and irradiation. Arch Neurol, 33: 494-500, 1976.
24. Walker MD, Alexander E Jr, Hunt WE, MacCarthy CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg, 49: 333-343, 1978.
25. Van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ: Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys, 47: 779-784, 2000.
26. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer, 83: 588-593, 2000.
27. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G, Beroukas K, Karageorgis P: Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol, 23: 2372-2377, 2005.
28. Chibbaro S, Benvenuti L, Caprio A, Carnesecchi S, Pulera F, Faggionato F, Serino D, Galli C, Andreuccetti M, Buxton N, Gagliardi R: Temozolomide as first-line agent in treating high-grade gliomas: phase II study. J Neurooncol, 67: 77-81, 2004.
29. Cionini L, Tagliagambe A, Fatigante L, Nocita M, Lenzi B, Cantini R, Iori C, Bergamini M, Massetani R, Barbieri L: A phase 2 study with concurrent and sequential temozolomide combined with radiation therapy in high grade gliomas. Int J Radiat Oncol Biol Phys, 51 (Suppl 3): S206, 2001.
30. Combs SE, Gutwein S, Schulz-Ertner D, Van Campen M, Wannenmacher M, Thilmann C, Debus J: Phase I/II-study of temozolomide combined with radiation as postoperative treatment in primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 60 (Suppl 1): S258-259, 2004.
31. Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A: Temozolomide in radiochemotherapy combined treatment for newly diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Res, 23: 5159-5164, 2003.
32. Mirimanoff R O, Mason W, Kortmann R, Van den Bent M, Fisher B, Taphoorn M, Reni M, Curschmann J: Radiotherapy (RT) and concomitant and adjuvant temozolomide (TMZ) versus radiotherapy alone for newly diagnosed glioblastoma (GBM): overall results and recursive partitioning analysis (RPA) of a phase III randomized trial of the EORTC Brain Tumor and Radiotherapy Groups and NCIC Clinical Trial Group. Int J Radiat Oncol Biol Phys, 60 (Suppl 1): S162, 2004.
33. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE: Recursive partitioning analysis of prognostic factors in the three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst, 85: 704-710, 1993.
34. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, Curran WJ Jr: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys, 40: 51-55, 1998.
35. MacDonald DR: New frontiers in the treatment of malignant glioma. Semin Oncol, 30: 72-76, 2003.
36. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res, 58: 4363-4367, 1998.
37. Baumann F, Bjeljac M, Kollias SS, Baumert BG, Brandner S, Rousson V, Yonekawa Y, Bernays RL: Combined thalidomide and temozolomide in patients with glioblastoma multiforme. J Neurooncol, 67: 191-200, 2004.
38. Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P: Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol, 131: 31-40, 2005.
39. Bartolomei M, Mazzetta C, Handkiewicz-Junak D, Bodei L, Rocca P, Grana C, Maira G, Sturiale C, Villa G, Paganelli G: Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. Q J Nucl Med Mol Imaging, 48: 220-228, 2004.
40. Ravizza R, Cereda E, Monti E, Gariboldi MB: The piperimide nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells. Int J Oncol, 25: 1817-1822, 2004.